HER2-Specific CAR T-Cell Therapy Active in Progressive GlioblastomaCancer NetworkAdministration of autologous HER2-specific chimeric antigen receptor (CAR)-modified virus specific T Cells (VSTs) was safe and had clinical benefit for some patients with … Continue reading
With new deal, company spun out of UNC moving forward in gene therapyTriangle Business JournalWith a new deal in hand, Durham-based StrideBio is moving forward in the gene therapy space. StrideBio is the result of technology from the labs of Aravind As… Continue reading
Vericel to Present at the 5th Annual Cell & Gene Therapy Investor DayGlobeNewswire (press release)CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) — Vericel Corporation (Nasdaq:VCEL), a leading developer of expanded autologous cell therapies for … Continue reading
|
Vericel to Present at the 5th Annual Cell & Gene Therapy Investor Day
Nasdaq CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) — Vericel Corporation (Nasdaq:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick … Homology Medicines to Present at the Alliance for Regenerative Medicine’s Cell & Gene Therapy Investor DayPR Newswire (press release) |
Immuno-Oncology News |
Ignyta’s RXDX-106 Works with Immune Checkpoint Inhibitors to Kill Tumors, Study Shows
Immuno-Oncology News Ignyta’s RXDX-106 can restore the body’s immune-system response against several types of tumors and work with immune checkpoint inhibitors to kill tumor cells, according to a company presentation at the American Association for Cancer Research annual … |
|
NYU Langone Research Leads to Accelerated Approval of Bladder Cancer Immunotherapy Drug
Newswise (press release) Clinical trial research led by Arjun V. Balar, MD, of NYU Langone’s Perlmutter Cancer Center, helped pave the way for the recent FDA approval of the immunotherapy drug atezolizumab as a first-line treatment for advanced bladder cancer. |
|
NYU Langone Research Leads to Accelerated Approval of Bladder Cancer Immunotherapy Drug
Newswise (press release) Clinical trial research led by Arjun V. Balar, MD, of NYU Langone’s Perlmutter Cancer Center, helped pave the way for the recent FDA approval of the immunotherapy drug atezolizumab as a first-line treatment for advanced bladder cancer. |